Ligand Pharmaceuticals (LGND) Cash from Operations Growth (1y) (2011 - 2026)
Ligand Pharmaceuticals (LGND) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 158.60% |
| 10 | Ligand Pharmaceuticals | 5.90 Bn | 5.12 Bn | 48.45 Mn | 291.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 291.36% |
| Dec 31, 2025 | 61.27% |
| Sep 30, 2025 | -64.17% |
| Jun 30, 2025 | 18.66% |
| Mar 31, 2025 | -235.84% |
| Dec 31, 2024 | 253.02% |
| Sep 30, 2024 | 377.77% |
| Jun 30, 2024 | 16,336.59% |
| Mar 31, 2024 | -44.82% |
| Dec 31, 2023 | -84.92% |
| Sep 30, 2023 | -62.68% |
| Jun 30, 2023 | -100.69% |
| Mar 31, 2023 | -34.73% |
| Dec 31, 2022 | 93.44% |
| Sep 30, 2022 | 2.32% |
| Jun 30, 2022 | -41.71% |
| Mar 31, 2022 | 383.64% |
| Dec 31, 2021 | 5,047.49% |
| Sep 30, 2021 | 57.12% |
| Jun 30, 2021 | -16.43% |